Specific Mutations in AML Affect Response to Therapy

Mar 15, 2012 - Patients with acute myeloid leukemia harboring specific combinations of mutations benefit from high-dose daunorubicin; and the majority of bone marrow cells in myelodysplastic syndromes and secondary acute myeloid leukemia are clonal and harbor multiple mutations, according to two studies published online March 14 in the New England Journal of Medicine.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More

OncoLink Cancer Treatment and Resources